SCHEMBL15030495

SCHEMBL15030495

COc1cccc(C(=O)Cn2cccc(C)c2=O)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDYL2 Q8N8U2 6/20 0.54
CDYL Q9Y232 6/20 0.54
CDY1; CDY1B Q9Y6F8 5/20 0.54
CA12 O43570 2/20 0.51
CA9 Q16790 2/20 0.51
CBX7 O95931 4/20 0.50
CA1 P00915 1/20 0.49
MAPT P10636 4/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
KDM4E B2RXH2 2/20 0.48
HPGD P15428 1/20 0.48
CHRM2 P08172 1/20 0.48
CHRM1 P11229 1/20 0.48
CHRM3 P20309 1/20 0.48
CES2 O00748 1/20 0.48
CES1 P23141 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15030415 0.85 ALDH1A1 (0.56) MAPTNPC1RAB9AKDM4EALDH1A1
SCHEMBL15030430 0.84 THRB (0.48) CDYL2CDYLCDY1; CDY1BMEN1KMT2A
SCHEMBL16806662 0.84 ALDH1A1 (0.45) MAPTMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL16161454 0.83 CYP19A1 (0.57) KMT2ASMN1; SMN2ALDH1A1TSHR
SCHEMBL15030431 0.83 ALDH1A1 (0.44) CA12CA9CA1MAPTMEN1
SCHEMBL15030562 0.82 PDE4B (0.61) CDYL2CDYLCDY1; CDY1BCBX7KDM4E
SCHEMBL15030528 0.82 THRB (0.49) MAPTMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL10871644 0.82 CDYL2 (0.59) CDYL2CDYLCDY1; CDY1BCA12CA9
SCHEMBL15030482 0.81 MEN1 (0.54) MAPTMEN1KMT2ASMN1; SMN2NPC1
SCHEMBL15030414 0.80 PDE4B (0.49) MAPTMEN1KMT2AKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000476-B2 Pyridone derivative, pharmaceutical containing the same and methods of use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2018-06-19 US disclosed
US-10000476-B2 Pyridone derivative, pharmaceutical containing the same and methods of use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2018-06-19 US disclosed
US-20160340349-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-11-24 US disclosed
US-20160340349-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-11-24 US disclosed
US-9447072-B2 Pyridone derivative and pharmaceutical containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-09-20 US disclosed
US-9447072-B2 Pyridone derivative and pharmaceutical containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-09-20 US disclosed
US-20160168540-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-06-16 US disclosed
US-20160168540-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-06-16 US disclosed
EP-3006029-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION Kaken Pharmaceutical Co., Ltd. (JP) 2016-04-13 EP disclosed
US-20150166506-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2015-06-18 US disclosed
US-20150166506-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2015-06-18 US disclosed
WO-2013085016-A1 PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME 科研製薬株式会社 (JP) 2013-06-13 WO disclosed
WO-2013085017-A1 PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME 科研製薬株式会社 (JP) 2013-06-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160340349-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME PLPBP, PDXK, PNPO CDYL2 4042/4885CDYL 3632/4885CDY1; CDY1B 1772/4885
US-10000476-B2 Pyridone derivative, pharmaceutical containing the same and methods of use thereof PNPO, PDXK, PLPBP CDYL2 3914/4885CDYL 3410/4885CDY1; CDY1B 1373/4885
US-20160168540-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION PF4, F2, PFKP CDYL2 4778/4885CDYL 4766/4885CDY1; CDY1B 3380/4885
US-20150166506-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME PLPBP, PDXK, PNPO CDYL2 4042/4885CDYL 3632/4885CDY1; CDY1B 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.